Navigation Links
Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
Date:10/22/2007

CAMBRIDGE, Mass., and NEW YORK, Oct. 22 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) and Bioenvision, Inc. (Nasdaq: BIVN) announced this afternoon that Bioenvision stockholders have voted to approve the acquisition of the company by Genzyme at a reconvened special shareholder meeting in New York. The transaction will be effective tomorrow. Bioenvision shares have now ceased trading and the company will be delisted from Nasdaq.

Fifty-six percent of Bioenvision's issued and outstanding shares of common stock and preferred stock, voting together as a single class on an as converted basis, supported the merger. This represents approximately 67 percent of the total shares voted.

With its acquisition of Bioenvision, Genzyme takes a significant step in enhancing its existing oncology business by gaining the exclusive, worldwide rights to clofarabine.

"We are very pleased that Bioenvision shareholders voted to support this merger," stated Mark J. Enyedy, president of Genzyme Oncology, a business unit of Genzyme Corporation. "We are deeply committed to furthering the clinical development of clofarabine and making it available on a global basis so that patients around the world with these very difficult forms of cancer will have access to the therapy. The successful completion of this acquisition creates the platform on which we will continue to build an international commercial presence for our oncology business."

Genzyme acquires Bioenvision in an all cash transaction valued at $5.60 per share, or approximately $345 million.

Christopher B. Wood, M.D., chairman and chief executive officer of Bioenvision, said, "We are pleased to conclude this merger process and we respect our shareholders' participation and opinions in this regard. We are confident in Genzyme's commitment to advance clofarabine, aided by their established clinical, regulatory and commercial infrastructure, and their already significant U.S. commercial experience with the compound."

Clofarabine is branded as Clolar(R) in the U.S. and Canada, where it is marketed by Genzyme for relapsed and refractory pediatric ALL patients. In Europe, Bioenvision and Genzyme co-developed clofarabine and Bioenvision currently markets the product under the brand name Evoltra(R), also for the treatment of relapsed and refractory pediatric ALL patients.

The companies have been developing clofarabine for significantly larger indications, including use as a first-line therapy for the treatment of adult acute myeloid leukemia (AML). Clofarabine has been granted orphan drug status for ALL and AML in both the United States and European Union.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,500 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was

selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including statements about the closing of acquisition of Bioenvision. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others: the possibility that the transaction is not completed; the possibility that certain closing conditions are not met, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R) and Clolar(R) are registered trademarks of Genzyme Corporation. Evoltra(R) is a registered trademark of Bioenvision, Inc. All rights reserved.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

CONTACTS:

For Genzyme For Bioenvision

Catherine E. Forte (investors) James S. Scibetta (investors)

(617) 768-6881 (212) 750-6700

Maria E. Cantor (media) Sondra S. Newman (media)

(617) 768-6690 (617) 877-5687


'/>"/>
SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. NEW ROBOTIC SURGERY ARM APPROVED BY FDA
2. Abortion Pill approved by FDA
3. Another injectable contraceptive Pill approved by FDA
4. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
5. New FDA Approved Drug To Treat Migraine
6. Lose Weight With New Wonder Slimming FDA approved Prescription Drug
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. FDA approves Phase 0 trial which tests experimental drugs on humans
9. FDA Approves Contraceptive Ring
10. FDA approves new device to treat womens bleeding disorder
11. FDA Approves New HIV Drug, Viread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... “Fruit of ... their imaginations while exploring nature that God has created. “Fruit of the Spirit: “Love”” ... Muslim, is now a devoted wife and mother of five. Halimah is an avid ...
(Date:9/22/2017)... ... September 22, 2017 , ... Egg freezing and embryo freezing ... have a slight statistical advantage for live births, frozen eggs offer many advantages, ... women undergoing medical treatment or who are concerned about the decline of their ...
(Date:9/21/2017)... ... September 21, 2017 , ... 38-Year-Old Plastic Surgeon Gill at Aesthetic Surgery Center ... pleased to announce that Plastic Surgeon Kiranjeet Gill has been awarded as one of ... an annual award that was started in 2003 to salute young achievers in Southwest ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... with Infinity Behavioral Health Services for professionals in the addiction treatment industry entitled: ... Audit . , Insurance companies and state and federal governments are increasingly ...
(Date:9/21/2017)... ... September 21, 2017 , ... Demonstrating a ... public health departments have been awarded five-year accreditation status through the Public ... of being served by a PHAB-accredited health department now extend to more ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)...  As the latest Obamacare repeal effort moves is ... (R-LA) and Lindsey Graham (R-SC) medical device ... industry is in an odd place.  The industry wants ... tax on medical device sales passed along with the ... increased visits and hospital customers with the funding to ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/13/2017)... 13, 2017   OrthoAtlanta has been named the ... Host Committee (AFHC) for the 2018 College Football Playoff (CFP) ... at Mercedes-Benz Stadium in Atlanta, Georgia . ... "I,m In" campaign, participating in many activities leading up to, ... ...
Breaking Medicine Technology: